clinical trial · NCT07221877
A Study to Evaluate the Effect of KarXT on Urological Safety
Bristol-Myers Squibb·phase4·recruiting·n = 60
SchizophreniaXanomeline/trospium chloride
brief summary
The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.
started
Jan 20, 2026
primary completion
Dec 30, 2027
completion
Dec 30, 2027
last updated
Jun 3, 2026
official title
A 12-month Open-label, Phase 4 Multicenter Safety Study to Evaluate the Effect of KarXT on Voiding Dynamics and Urological Safety
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol